KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Operating Leases (2019 - 2025)

Neogenomics (NEO) has disclosed Operating Leases for 7 consecutive years, with $64.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 3.46% year-over-year to $64.3 million, compared with a TTM value of $64.3 million through Sep 2025, up 3.46%, and an annual FY2024 reading of $60.8 million, down 10.36% over the prior year.
  • Operating Leases was $64.3 million for Q3 2025 at Neogenomics, down from $66.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $73.4 million in Q1 2022 and bottomed at $46.4 million in Q1 2021.
  • Average Operating Leases over 5 years is $65.0 million, with a median of $65.5 million recorded in 2023.
  • The sharpest move saw Operating Leases soared 70.91% in 2021, then decreased 12.01% in 2023.
  • Year by year, Operating Leases stood at $72.3 million in 2021, then decreased by 4.62% to $69.0 million in 2022, then fell by 1.57% to $67.9 million in 2023, then dropped by 10.36% to $60.8 million in 2024, then rose by 5.73% to $64.3 million in 2025.
  • Business Quant data shows Operating Leases for NEO at $64.3 million in Q3 2025, $66.6 million in Q2 2025, and $59.9 million in Q1 2025.